
PROVENGE (sipuleucel-T)
PROVENGE is personal PROVENGE is the first FDA-approved personalized immunotherapy for treatment of advanced prostate cancer. It has been clinically proven to extend life for certain men …
About PROVENGE – PROVENGE (sipuleucel-T)
PROVENGE ® (sipuleucel-T) is a prescription medicine used to treat certain men with advanced prostate cancer. PROVENGE is an established cellular immunotherapy and is customized to each …
Your PROVENGE Journey – PROVENGE (sipuleucel-T)
PROVENGE ® (sipuleucel-T) is a prescription medicine used to treat certain men with advanced prostate cancer. PROVENGE is an established cellular immunotherapy and is customized to each …
Immunotherapy – PROVENGE (sipuleucel-T)
PROVENGE ® (sipuleucel-T) is a prescription medicine used to treat certain men with advanced prostate cancer. PROVENGE is an established cellular immunotherapy and is customized to each …
PROVENGE® (sipuleucel-T) for Healthcare Providers
PROVENGE ® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate …
Prolonged Survival - HCP
PROVENGE success rate using immunotherapy for advanced prostate cancer, Learn about clinical trial results for advanced prostate cancer life expectancy.
Safety - HCP
Learn about side effects of PROVENGE sipuleucel-T treatment for advanced prostate cancer.
Patient Testimonials – PROVENGE (sipuleucel-T)
PROVENGE® (sipuleucel-T) had recently become available as a personalized immunotherapy made from a patient’s own immune cells. It activates the body’s ability to keep fighting advanced prostate …
PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate …
The PROVENGE treatment can be completed about a month power your immune system. This process can be completed in 6 appointments, outlined on the previous page, throug out th month. It is …